Corbus Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- 1
- Market Cap
- $689.3M
- Website
- http://www.corbuspharma.com
First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.
- Conditions
- Solid Tumor
- Interventions
- Drug: CRB-601 monoclonal antibodyDrug: Anti-PD-1 monoclonal antibodyRadiation: Immune-priming single lesion SBRT
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT06603844
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸SCRI - Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT06265727
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸Moores Cancer Centre at UC San Diego Health, San Diego, California, United States
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
- Conditions
- Dermatomyositis
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT03813160
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Pittsburgh, Division of Rheumatology, Pittsburgh, Pennsylvania, United States
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT03451045
- Locations
- 🇦🇹
Cystic Fibrosis Centre Innsbruck Medical University of Innsbruck, Dept. for Child and Adolescent Health, University Clinic for Paediatrics, Cardiology, Pneumology, Allergology, Cystic Fibrosis, Innsbruck, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
🇧🇪Universitair Ziekenhuis Brussel, Brussels, Belgium
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT03398837
- Locations
- 🇺🇸
John Hopkins University, Scleroderma Center, Baltimore, Maryland, United States
🇺🇸The Steffens Scleroderma at The Center for Rheumatology, Albany, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02466243
- Locations
- 🇺🇸
University of Pennsylvania Perlman School of Medicine, Philadelphia, Pennsylvania, United States
Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT02465450
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇬🇧Belfast City Hospital, Belfast, United Kingdom
🇵🇱Instytut Gruźlicy i Chorób Płuc I Klinika Chorób Płuc, Warszawa, Poland
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02465437
- Locations
- 🇺🇸
Arthritis Association of Southern CA, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸John Hopkins Scleroderma Center, Baltimore, Maryland, United States